{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:37:24Z","timestamp":1768487844119,"version":"3.49.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:p>Heart transplantation (HT) has become the preferred treatment for end-stage heart disease, but postoperative complications such as infection still threaten the prognosis of HT patients. Basiliximab can help minimize immune rejection. However, there is a lack of relevant information to compare the prognosis of different immunosuppression regimens. This study aimed to investigate the risk factors associated with death and infection after HT surgery. We also provide some insightful information on the administration of basiliximab to improve the prognosis of HT patients. In total, 70 patients were included in this retrospective observational study. All participants underwent primary HT and were administered immunosuppressive agents postoperatively. Of these, 38 received additional basiliximab. There was a 6-month follow-up period after HT during which clinical outcomes were monitored. Logistic regression and cox-proportional hazard regression analyses were performed to determine the relationship between basiliximab use and the clinical outcomes of HT. Logistic regression analysis revealed that basiliximab use (odds ratio [OR]\u2005=\u20050.07, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.014) was an independent risk factor for death after HT. <jats:sc>d<\/jats:sc>-Dimer (OR\u2005=\u20059.05, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.002) and basiliximab use (OR\u2005=\u20050.15, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.004) were independent risk factors for death after HT. Moreover, patients treated with basiliximab had shorter hospital lengths of stay (23.58\u2005\u00b1\u200513.89 vs 39.41\u2005\u00b1\u200524.43, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001) and intensive care unit lengths of stay (4.76\u2005\u00b1\u20052.85 vs 11.25\u2005\u00b1\u20055.79, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). Furthermore, patients administered basiliximab had lower rates of death (1 [5.4%] vs 9 [28.1%], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.007) and infection (6 [15.8%] vs 19 [59.4%], <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). The postoperative survival rate (hazard ratio 0.08, 95% confidence interval 0.01\u20130.65, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.018) and survival against infection (hazard ratio 0.24, 95% confidence interval 0.09\u20130.64, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.004) were significantly higher among patients receiving basiliximab treatment than among those not receiving treatment. Our study showed that basiliximab use was closely associated with the rate of postoperative death and infection after HT. HT patients with additional basiliximab administration as immunosuppressive treatment had a better clinical prognosis.<\/jats:p>","DOI":"10.1097\/md.0000000000036504","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:09:19Z","timestamp":1708535359000},"page":"e36504","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effect of basiliximab use on the risk of postoperative infection and death after heart transplantation: An observational study"],"prefix":"10.1097","volume":"102","author":[{"given":"Fangxu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, the General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Emergency, the 967th Hospital of Joint Logistics Support Force of Chinese PLA, Dalian, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Entao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, the General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songzhe","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, the General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, the General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.healun.2013.08.005","article-title":"The registry of the international society for heart and lung transplantation: sixteenth official pediatric heart transplantation report\u20142013; focus theme: age.","volume":"32","author":"Dipchand","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update.","volume":"35","author":"Mehra","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"633","DOI":"10.12968\/hmed.2012.73.11.633","article-title":"Surgical management of end-stage heart failure.","volume":"73","author":"Sharkey","year":"2012","journal-title":"Br J Hosp Med (Lond)"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.healun.2017.05.009","article-title":"Bacterial infections after pediatric heart transplantation: epidemiology, risk factors and outcomes.","volume":"36","author":"Rostad","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.healun.2015.08.005","article-title":"The registry of the international society for heart and lung transplantation: eighteenth official pediatric lung and heart-lung transplantation report\u20142015; focus theme: early graft failure.","volume":"34","author":"Goldfarb","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1097\/TP.0000000000003307","article-title":"Recent trends of infectious complications following heart transplantation.","volume":"104","author":"Multani","year":"2020","journal-title":"Transplantation"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/sur.2019.073","article-title":"In-hospital post-operative infection after heart transplantation: epidemiology, clinical management, and outcome.","volume":"21","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Surg Infect"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"e13104","DOI":"10.1111\/tid.13104","article-title":"In-hospital postoperative infection after heart transplantation: risk factors and development of a novel predictive score.","volume":"21","author":"Fern\u00e1ndez-Ugidos","year":"2019","journal-title":"Transplant Infect dis"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1399-3062.2011.00646.x","article-title":"Epidemiology and risk factors for late infection in solid organ transplant recipients.","volume":"13","author":"Cervera","year":"2011","journal-title":"Transplant Infect Dis"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.","volume":"29","author":"Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.healun.2004.09.010","article-title":"A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation.","volume":"24","author":"Mehra","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R13-20250503","first-page":"191","article-title":"Basiliximab and heart transplantation in Hispanics: the experience in Puerto Rico.","volume":"99","author":"Banchs","year":"2007","journal-title":"Bol Asoc Med P R"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/650482","article-title":"Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America.","volume":"50","author":"Hooton","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/sur.2016.048","article-title":"Prevention of hospital-acquired infections.","volume":"17","author":"Dellinger","year":"2016","journal-title":"Surg Infect"},{"key":"R18-20250503","first-page":"329","article-title":"Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study.","volume":"15","author":"Smart","year":"1996","journal-title":"J Heart Lung Transplant"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/ajt.17130","article-title":"Post-transplant mortality and graft failure after induction immunosuppression among Black heart transplant recipients in the United States.","volume":"22","author":"Salia","year":"2022","journal-title":"Am J Transplant"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ctr.12469","article-title":"Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.","volume":"29","author":"Whitson","year":"2015","journal-title":"Clin Transplant"},{"key":"R21-20250503","first-page":"CD008842","article-title":"Immunosuppressive T-cell antibody induction for heart transplant recipients.","volume":"(12)","author":"Penninga","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"e002790","DOI":"10.1161\/JAHA.115.002790","article-title":"Comparison of basiliximab and anti-thymocyte globulin as induction therapy in pediatric heart transplantation: a survival analysis.","volume":"5","author":"Ansari","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.healun.2015.04.001","article-title":"Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab.","volume":"34","author":"Ansari","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.healun.2009.09.001","article-title":"Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.","volume":"28","author":"Grundy","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients CHIB 201 International Study Group.","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet (London, England)"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccc.2018.03.009","article-title":"A targeted management approach to cardiogenic shock.","volume":"34","author":"Chakravarthy","year":"2018","journal-title":"Crit Care Clin"},{"key":"R27-20250503","first-page":"364","article-title":"Infection in patients with decompensated heart failure: in-hospital mortality and outcome.","volume":"110","author":"Cardoso","year":"2018","journal-title":"Arq Bras Cardiol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healun.2003.09.043","article-title":"Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction.","volume":"24","author":"Delgado","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"e13871","DOI":"10.1111\/ctr.13871","article-title":"Induction immunosuppression strategies and long-term outcomes after heart transplantation.","volume":"34","author":"Nozohoor","year":"2020","journal-title":"Clin Transplant"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.transproceed.2008.07.113","article-title":"Induction immunosuppression with basiliximab in heart transplantation.","volume":"40","author":"Chou","year":"2008","journal-title":"Transplant Proc"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003495-199957020-00006","article-title":"Basiliximab.","volume":"57","author":"Onrust","year":"1999","journal-title":"Drugs"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0009-9236(98)90024-8","article-title":"Disposition and immunodynamics of basiliximab in liver allograft recipients.","volume":"64","author":"Kovarik","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.transproceed.2005.02.026","article-title":"Basiliximab in lung transplantation: preliminary experience.","volume":"37","author":"de la Torre","year":"2005","journal-title":"Transplant Proc"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2004.08.003","article-title":"Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation.","volume":"24","author":"Rosenberg","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.transproceed.2005.09.176","article-title":"Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.","volume":"37","author":"Gonz\u00e1lez","year":"2005","journal-title":"Transplant Proc"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.healun.2007.05.002","article-title":"Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.","volume":"26","author":"Mattei","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"e13190","DOI":"10.1111\/petr.13190","article-title":"Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: an analysis of the International Society for Heart and Lung Transplantation database.","volume":"22","author":"Butts","year":"2018","journal-title":"Pediatr Transplant"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/ajt.12514","article-title":"A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations.","volume":"13","author":"Popow","year":"2013","journal-title":"Am J Transplant"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2340\/00015555-2046","article-title":"Low-dose anti-thymocyte globulin inhibits human B-cell differentiation into antibody-secreting cells.","volume":"95","author":"Klaus","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.healun.2007.01.006","article-title":"Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.","volume":"26","author":"Carrier","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation.","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:27:24Z","timestamp":1746318444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":41,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036504","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}